Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 2, 2007, Pages 143-153

  Karnon, Jonathan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anatrozole; Cost effectiveness; Early breast cancer; Exemestane letrozole

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ADVANCED CANCER; ARTHRALGIA; ARTHRITIS; BLEEDING; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG COST; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; HEART FAILURE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SOFT TISSUE METASTASIS; SURVIVAL TIME; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VISCERAL METASTASIS;

EID: 34247891754     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.2.143     Document Type: Review

References (34)

1. Ferlay J, Bray F, Pisani P et al. Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0: IARC CancerBase no.5, Lyon, LARC Press (2004).
2. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence, January (2006).
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
4. ATAC Trialists' Group, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
5. BIG 1-98 Collaborative Group. A comparison of letrozole with tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757(2005).
6. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
7. Coombes RC, Hall E, Snowdon CF, Bliss JM, The Intergroup Exemestane Study: a randomised trial in postmenopausal patients with early breast cancer who remain disease-fire after two to three years of tamoxifen - updated survival analysis. Breast Cancer Res. Treat. 88, S7 (2004) (Abstract 3).
8. Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole (ANA) versus continued tamoxifen (TAM) treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Proc. Am. Soc. Clin. Oncol. 23, S10 (2005) (Abstract 526).
9. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
10. Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annal. Oncol. 17(2), 217-225 (2006).
11. Karnon J, Delea TE, Barghout V. Cost utility analysis of early adjuvant letrozole vs tamoxifen, and anastrozole vs tamoxifen, in postmenopausal women: the UK perspective (submitted to European Journal of Health Economics).
12. Delea TE, Karnon J, Thomas SK, Barghout V, Papa NL, Johnston SRD. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective. Breast Cancer Res. Treat. 94(Suppl. 1), S102 (2005).
13. National Institute for Health and Clinical Excellence, Final Appraisal Determination: hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer, August (2006).
14. Mouridsen H,Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19, 2596-2606 (200 1) Erratum in: J. Clin. Oncol. 19, 3302 (2001).
15. Sorensen S, Brown I, Benedict A, Flood E, Revicki D. Patient-rated utilities in postmenopausal early breast cancer: a cross country comparison, ISPOR 7th Annual European Congress, 24-26 October, Hamburg, Germany (2004).
16. Brown R, Benedict A, Mansel R. Cost-effectiveness of anastrozole versus tamoxifen in postmenopausal women with HR+ early breast cancer hom a UK National Health Service perspective: the 5-year completed treatment analysis ofthe ATAC trial, ISPOR 8th Annual European Congress, 6-8 November, Florence, Italy (2005).
17. Brown R, Benedict A, Mansel R. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK National Health Service perspective, ISPOR 7th Annual European Congress, 24-26 October, Hamburg, Germany (2004),
18. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 6, 1311-1322 (2004).
19. Locker GY. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare perspective. The ATAC Trialists' Group. Breast Cancer Res. Treat. 88 (Suppl. 1), S105 (2004).
20. Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: tamoxifen vs. anastrazole vs. tamoxifen then exemestane. Breast Cancer Res. Treat. 94(Suppl. 1), S217-S218 (2005).
21. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Supp. Care Cancer 14(9), 917-927 (2006).
22. Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast (2007) (Epub ahead of print).
23. Moeremans K, Annemans L. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int. J. Gynecol. Cancer 16(Suppl. 2), 576-578 (2006).
24. Will BP, Berthelot J-M, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur. J. Cancer 36, 724-735 (2000).
25. Karnon J, Kaura S, di Trapani F. Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal. San Antonio Breast Cancer Symposium, December (2006).
26. Wilson K, Wordsworth S, Tabberer M et al. Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model, EJC Supplements, 4(2), 151 (2006).
27. Thompson D, Taylor DCA, Montoya EL, Winer E, Weinstein MC. Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Res. Treat. 94 (Suppl. 1), S218 (2005).
28. Lundkvist, J, Wilking, N, Holmberg, S, Lidgren, M, Jonsson, L. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden, EJC Supplements, 4(2), 152 (2006).
29. Risebrough NA, Verma S, Trudeau M, Charbonneau C, Mittmann N. Economic evaluation of switching to exemestane at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: a Canadian perspective. Breast Cancer Res. Treat. 94(Suppl. 1), S1O1 (2005).
30. Kanis JA, Brazier JE, Stevenson M et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 6, 29 (2002).
31. Delea TE, Karnon J, Smith RE et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am. J. Managed Care 12(7), 374-386 (2006).
32. Karnon J, Delea T, Johnston SRD et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 24(3), 237-250 (2006).
33. Karnon J, Kaura S, Ditrapani F. Letrozole is more cost-effective than tamoxifen as early adjuvant therapy in multiple sub-groups of postmenopausal women with early breast cancer: the UK perspective. San Antonio Breast Cancer Symposium, December (2006).
34. Craig Jordan V, Optimising endocrine approaches for the chemoprevention of breast cancer: Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. Eur. J. Cancer 42, 2909-2913 (2006).